AstraZeneca Korea said Kim Sang-pyo took office as its new CEO on Monday. Kim had led MSD Korea’s oncology department from 2016 after acquiring more than 10 years of experience in the industry.
|AstraZeneca Korea's new CEO Kim Sang-pyo|
The Korean branch of AstraZeneca expressed high expectations for Kim, saying that his experience in the field of oncology will help expand the company’s anticancer portfolio.
“Kim’s various experiences and insights will lead AstraZeneca to reach new heights as the company is currently expanding its anticancer drug portfolio,” the company said in a statement.
<© Korea Biomedical Review, All rights reserved.>